Business:
Genetic Neuroscience Treatments
Drug notes:
Also Clin2 essential tremor; PRAX-562 Clin2 epilepsy; PRAX-628 Clin1 focal epilepsy; PRAX-222 Clin1 epilepsy; 6 programs Clin0 CNS disorders
About:
Praxis Precision Medicines is developing therapies for central nervous system (CNS) disorders by using insights from genetics. CNS disorders are characterized by neuronal excitation-inhibition imbalance. Praxis is using four key principles to increase the probability of success of finding therapies: [1] genetics to focus on targets identified through human genetics, [2] translational tools, to validate targets, [3] patient-guided development strategies and [4] efficient and rigorous clinical development paths. Praxis currently has two lead clinical programs for Epilepsy - CerebrumTM, a small molecule platform and SolidusTM, an antisense oligonucleotide platform.
****** *******, ******** ** ****** ******|9 days ago
Senior Regulatory Submissions Manager United States|20 days ago
Office Experience & Events Lead United States|31 days ago
Principal Scientist, Formulation Development United States|31 days ago
******** / **. ********, ********** ****** ******|39 days ago
Director, Clinical Supplies Management United States|42 days ago
Manager, Investor Relations United States|45 days ago